IDEAYA Biosciences Presents Complete Phase 2/3 Darovasertib Data at ASCO, Reinforcing Strong Efficacy
IDYA sits 49% above its 52-week low of $19.48.
Summary
IDEAYA Biosciences presented complete Phase 2/3 clinical trial data for darovasertib at ASCO, demonstrating significant improvements in progression-free survival, objective response rate, and disease control rate in metastatic uveal melanoma.
Key Events · Product Development and Regulatory · IDYA
-
Complete Phase 2/3 Data Presented
IDEAYA Biosciences and Servier presented complete data from the registrational Phase 2/3 OptimUM-02 trial of darovasertib in combination with crizotinib for first-line HLA*A2:01 negative metastatic uveal melanoma at the 2026 ASCO Annual Meeting.
-
Primary Endpoint Met with Strong Efficacy
The trial met its primary endpoint, showing a statistically significant improvement in median progression-free survival (PFS) of 6.9 months versus 3.1 months in the control arm (HR: 0.42; p-value: <0.0001), representing a 58% reduction in disease progression risk.
-
Significant Improvement in Secondary Endpoints
The darovasertib combination achieved an objective response rate (ORR) of 37.1% versus 5.8% in the control arm, and a disease control rate (DCR) of 73.3% versus 31.1% (both p-value: <0.0001).
-
Manageable Safety Profile
The darovasertib combination was generally well-tolerated with a manageable safety profile consistent with previous results, and a low discontinuation rate due to treatment-related adverse events.
Analysis · IDYA · Life Sciences
IDEAYA Biosciences presented complete data from its registrational Phase 2/3 OptimUM-02 trial for darovasertib in metastatic uveal melanoma at ASCO. This filing provides the full, detailed clinical results, confirming the previously announced positive topline data. The strong efficacy and manageable safety profile support the drug's potential as a new therapeutic standard and bolster the ongoing FDA Real-Time Oncology Review process, with an NDA filing expected in the second half of 2026.
How filings like this one have moved
In the 30 days to Oct 4, 2026, 36.7% of the 1015 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IDYA was trading at $28.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $19.48 to $39.28. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.